NCT02432703View on ClinicalTrials.gov

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

PHASE2CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

June 11, 2015

Primary Completion Date

August 9, 2018

Study Completion Date

August 9, 2018

Conditions

Phobic Disorders

Interventions

DRUG

JNJ-42165279

Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.

DRUG

Placebo

Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.

Trial Locations (21)

Unknown

La Jolla

Hartford

Orlando

Chicago

Boston

Natick

New York

Rochester

Staten Island

Allentown

Reading

Dallas

Salt Lake City

Adelaide

Frankston

Melbourne

Perth

Edmonton

Hamilton

Mississauga

Toronto

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02432703 - A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder | Biotech Hunter | Biotech Hunter